Vivus Fattens Wallet with $45.8 million offering to support obesity drug
This article was originally published in Scrip
Still trying to get its experimental weight loss drug Qnexa (phentermine/topiramate) approved in the US – and having to sink some more cash into that endeavour – Vivus raised $45.8 million from selling 6.9 million shares of its common stock at $6.65 per share to a select group of institutional investors – an offering that was consummated on 24 August.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.